These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

107 related articles for article (PubMed ID: 33194628)

  • 1. Case Report: A Chronological Combination Treatment of Icotinib, Osimertinib, and Crizotinib on Lung Adenocarcinoma Guided by Serial Genetic Tests of Circulating Tumor DNA and Sediment Cell Genomic DNA From Pleural Effusion.
    Miao Z; Mu T; Liu L; Rao J; Jin M; Wang Z; Wang H; Lu C; Gong X; Zheng D; Zheng D; Li X; Li Y; Chen S; Shu X
    Front Oncol; 2020; 10():561341. PubMed ID: 33194628
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Case Report: Durable partial response to icotinib plus crizotinib in a lung adenocarcinoma patient with double uncommon
    Ou L; Tang Y; Deng Y; Guo L; He Q; He T; Feng W
    Front Oncol; 2022; 12():911362. PubMed ID: 35957915
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined therapy with osimertinib and afatinib in a lung adenocarcinoma patient with EGFR T790M mutation and multiple HER2 alterations after resistance to icotinib: A case report.
    Zhang P; Nie X; Wang B; Li L
    Thorac Cancer; 2018 Dec; 9(12):1774-1777. PubMed ID: 30295016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of osimertinib treatment on lung adenocarcinoma with squamous cell transformation harboring the T790M mutation: A case report and literature review.
    Yamaguchi F; Kato E; Wakabayashi A; Shikama Y
    Mol Clin Oncol; 2019 Aug; 11(2):127-131. PubMed ID: 31316771
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dramatic intracranial response to osimertinib in a poor performance status patient with lung adenocarcinoma harboring the epidermal growth factor receptor T790M mutation: A case report.
    Uemura T; Oguri T; Okayama M; Furuta H; Kanemitsu Y; Takakuwa O; Ohkubo H; Takemura M; Maeno K; Ito Y; Niimi A
    Mol Clin Oncol; 2017 Apr; 6(4):525-528. PubMed ID: 28413660
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Squamous cell transformation and
    Bruno R; Proietti A; Alì G; Puppo G; Ribechini A; Chella A; Fontanini G
    Oncol Lett; 2017 Nov; 14(5):5947-5951. PubMed ID: 29113230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effective treatment of pulmonary adenocarcinoma harboring triple EGFR mutations of L858R, T790M, and
    Zhao J; Zou M; Lv J; Han Y; Wang G; Wang G
    Onco Targets Ther; 2018; 11():5545-5550. PubMed ID: 30233215
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effective targeted therapy based on dynamic monitoring of gene mutations in non-small cell lung cancer.
    Deng T; Tang J; Zhou L; Duan H
    Transl Lung Cancer Res; 2019 Aug; 8(4):532-538. PubMed ID: 31555526
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Detection of EGFR Mutations in Circulating Tumor DNA (ctDNA) Retrieved from Plasma - Interlaboratory Quality Assessment in the Czech Republic.
    Linda Č; Markéta K; Ivana T; Eva P; Milada M; Hana V; Ondřej H; Karolína B; Jiří D; Monika B; Pavel D
    Klin Onkol; 2018; 31(5):353-360. PubMed ID: 30541321
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Significant benefits of osimertinib in treating acquired resistance to first-generation EGFR-TKIs in lung squamous cell cancer: A case report.
    Zhang Y; Chen HM; Liu YM; Peng F; Yu M; Wang WY; Xu H; Wang YS; Lu Y
    World J Clin Cases; 2019 May; 7(10):1221-1229. PubMed ID: 31183356
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Differential response to a combination of full-dose osimertinib and crizotinib in a patient with
    Zhu VW; Schrock AB; Ali SM; Ou SI
    Lung Cancer (Auckl); 2019; 10():21-26. PubMed ID: 30881166
    [TBL] [Abstract][Full Text] [Related]  

  • 12.
    Klempner SJ; Mehta P; Schrock AB; Ali SM; Ou SI
    Lung Cancer (Auckl); 2017; 8():241-247. PubMed ID: 29255376
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cytological-negative pleural effusion can be an alternative liquid biopsy media for detection of EGFR mutation in NSCLC patients.
    Song Z; Wang W; Li M; Liu J; Zhang Y
    Lung Cancer; 2019 Oct; 136():23-29. PubMed ID: 31421258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Management of advanced non-small cell lung cancers with known mutations or rearrangements: latest evidence and treatment approaches.
    Shea M; Costa DB; Rangachari D
    Ther Adv Respir Dis; 2016 Apr; 10(2):113-29. PubMed ID: 26620497
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monitoring of treatment responses and clonal evolution of tumor cells by circulating tumor DNA of heterogeneous mutant EGFR genes in lung cancer.
    Imamura F; Uchida J; Kukita Y; Kumagai T; Nishino K; Inoue T; Kimura M; Oba S; Kato K
    Lung Cancer; 2016 Apr; 94():68-73. PubMed ID: 26973209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MET Y1003S point mutation shows sensitivity to crizotinib in a patient with lung adenocarcinoma.
    Miao YL; Xu QQ
    Lung Cancer; 2019 Apr; 130():84-86. PubMed ID: 30885356
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical Features of Patients with an Epidermal Growth Factor Receptor T790M Mutation Detected in Circulating Tumor DNA.
    Ikushima H; Sakatani T; Usui K
    Oncology; 2020; 98(1):23-28. PubMed ID: 31494653
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Evaluation of Consistency in detection of epidermal growth factor receptor gene T790M mutation in plasma and tumor specimens of patients with lung adenocarcinoma].
    Du J; Wang Z; Yang L; Di J; Zhang JG; Wang TY; Liu DG
    Zhonghua Zhong Liu Za Zhi; 2018 Jan; 40(1):35-39. PubMed ID: 29365415
    [No Abstract]   [Full Text] [Related]  

  • 19. Retrospective analysis of icotinib neoadjuvant therapy of 63 lung cancer patients.
    Wang T; Liu Y; Zhou B; Hao S; Wang Z; Liang N; Liu J; Wang S
    Indian J Cancer; 2017; 54(1):215-222. PubMed ID: 29199694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Durable Response to Osimertinib in a Chinese Patient with Metastatic Lung Adenocarcinoma Harboring a Rare EGFR L858R/D761Y Compound Mutation.
    Zhu Y; Tang J; Li X; Qin T; Wei Y
    Onco Targets Ther; 2020; 13():10447-10451. PubMed ID: 33116624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.